Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1997 2
1998 1
2005 1
2006 2
2007 3
2009 1
2010 1
2011 2
2012 4
2013 1
2014 7
2015 11
2016 3
2017 3
2019 1
2020 1
2021 2
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27020167

47 results

Results by year

Filters applied: . Clear all
Page 1
SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma.
Duran I, Hagen C, Arranz JÁ, Apellaniz-Ruiz M, Pérez-Valderrama B, Sala N, Lainez N, García-Del Muro X, Noguerón E, Climent MÁ, Maroto P, Font A, García-Donas J, Gallardo E, López-Criado P, González Del Alba A, Sáez MI, Vázquez S, Luque R, Rodríguez-Antona C. Duran I, et al. Pharmacogenomics. 2016 Apr;17(5):463-71. doi: 10.2217/pgs.15.186. Epub 2016 Mar 29. Pharmacogenomics. 2016. PMID: 27020167 Clinical Trial.
Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.
Herrero Rivera D, Vacas CG, Kovandzic LM, Vázquez JP, Alonso LA, González BM, Aragón VC, Grande E, Caro RL, Virizuela Echaburu JA, Rodríguez Moreno JF, Etxebarria AA, Rodríguez-Antona C, Durán I. Herrero Rivera D, et al. Pharmacogenomics. 2022 Jul;23(11):627-638. doi: 10.2217/pgs-2022-0023. Epub 2022 Jul 26. Pharmacogenomics. 2022. PMID: 35880554
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
Bellmunt J, Kerst JM, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera MB, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh AJM, Pujol E, Perez-Gracia JL, González Larriba JL, Collado R, Los M, Maciá S, De Wit R; SOGUG and DUOS. Bellmunt J, et al. Ann Oncol. 2017 Jul 1;28(7):1517-1522. doi: 10.1093/annonc/mdx186. Ann Oncol. 2017. PMID: 28419193 Free article. Clinical Trial.
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.
Belderbos BPS, de With M, Singh RK, Agema BC, El Bouazzaoui S, Oomen-de Hoop E, de Wit R, van Schaik RHN, Mathijssen RHJ, Bins S. Belderbos BPS, et al. Cancer Chemother Pharmacol. 2020 Mar;85(3):547-553. doi: 10.1007/s00280-019-04011-0. Epub 2020 Jan 1. Cancer Chemother Pharmacol. 2020. PMID: 31893292 Clinical Trial.
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
Bambury RM, Benjamin DJ, Chaim JL, Zabor EC, Sullivan J, Garcia-Grossman IR, Regazzi AM, Ostrovnaya I, Apollo A, Xiao H, Voss MH, Iyer G, Bajorin DF, Rosenberg JE. Bambury RM, et al. Oncologist. 2015 May;20(5):508-15. doi: 10.1634/theoncologist.2014-0354. Epub 2015 Apr 6. Oncologist. 2015. PMID: 25845990 Free PMC article.
Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H, Delakas D, Anezinis P, Haldeopoulos D, Mazonakis M, Damilakis J, Metaxaris G, Chondros N, Mavromanolakis E, Daskalopoulos G, Dimitrakopoulos A, Kranidis A. Varveris H, et al. Anticancer Res. 1997 Nov-Dec;17(6D):4771-80. Anticancer Res. 1997. PMID: 9494605 Clinical Trial.
47 results